Manufacturers report positive data for ribociclib in breast cancer

Manufacturers report that exploratory subgroup analyses of the Phase III MONALEESA-3 and MONALEESA-7 trials noted an overall survival benefit from treatment (20% & 30% reduction in death in postmenopausal and premenopausal women in these trials respectively vs control).

Source:

PharmaTimes